HIGHLIGHTS
- who: Report and colleagues from the Pediatric Nephrology, University of Iowa, Iowa City, USA have published the research work: Review began 04/18/2022 Review ended 05/14/2022 Published 05/18/2022 u00a9 Copyright, in the Journal: (JOURNAL) of May/18,/2022
- what: Although the patient from the review had the same risk factors as the patient (being pediatric and having the underlying autoimmune disorder SLE) the patient from the review did relapse after discontinuation of eculizumab therapy.
- future: The case alone suggests that eculizumab can successfully be discontinued without relapse but . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.